Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181100 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
A Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Metastatic Thyroid Gland Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03181100 is a Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Metastatic Thyroid Gland Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, above the 25-participant average among 6 other Poorly Differentiated Thyroid Gland Carcinoma trials with a reported enrollment target (100% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03181100, a Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Metastatic Thyroid Gland Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well atezolizumab in combination with chemotherapy works in treating patients with anaplastic or poorly differentiated thyroid cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vemurafenib and cobimetinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of cancer cells to grow and spread. Drugs such as nab-paclitaxel and paclitaxel work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to see if atezolizumab in combination with chemotherapy works better in treating patients with anaplastic or poorly differentiated thyroid cancer compared to standard treatments.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
- BIOLOGICAL Bevacizumab
- DRUG Cobimetinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-07-27 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03181100
The ClinicalTrials.gov registry entry for NCT03181100 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 25-participant average among 6 other Poorly Differentiated Thyroid Gland Carcinoma trials with a reported enrollment target (100% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Poorly Differentiated Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT03181100 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03181100 about?
NCT03181100 is a clinical study titled "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer". This phase II trial studies how well atezolizumab in combination with chemotherapy works in treating patients with anaplastic or poorly differentiated thyroid cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfer...
What is the current status of trial NCT03181100?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2017-07-27. Estimated completion is 2027-07-31.
What conditions does trial NCT03181100 study?
This clinical trial studies the following conditions: Poorly Differentiated Thyroid Gland Carcinoma, Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8.
What interventions are being tested in trial NCT03181100?
The interventions under investigation include: Atezolizumab (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT03181100?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03181100 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Poorly Differentiated Thyroid Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Poorly Differentiated Thyroid Gland Carcinoma
All registered trials for this condition
Metastatic Thyroid Gland Carcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.